Abstract
A 75-year-old patient was diagnosed with a Gleason 9 prostate carcinoma. His PSA level was 50.4 ng/ml. Routine bone scintigraphy was negative for metastasis (a). Due to the high tumour grading and relatively high PSA level, 68Ga-PSMA PET-CT was ordered to rule out distant metastases. This scan showed numerous skeletal lesions with high tracer accumulation as sign of diffuse osseous metastases (b). On low-dose CT there were no signs of sclerosis (c). 68Ga-PSMA PET-CT also showed high uptake in the prostate and in para-iliac and para-aortal lymph nodes, without lymph node enlargement. No bone biopsy was obtained to confirm the metastases. Due to this result, the treatment plan was changed to systemic therapy, instead of local therapy.
Reference
Afshar Oromieh A, Avtzi E, Giesel FL, HollandLetz T, Linhart HG, Eder M, et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:197–209.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
None.
Conflicts of interest
The authors declare they do not have any conflicts of interest.
Rights and permissions
About this article
Cite this article
Lavalaye, J., Kaldeway, P. & van Melick, H.H.E. Diffuse bone metastases on 68Ga-PSMA PET-CT in a patient with prostate cancer and normal bone scan. Eur J Nucl Med Mol Imaging 43, 1563–1564 (2016). https://doi.org/10.1007/s00259-016-3398-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00259-016-3398-1